Physician profile
David S Morris
NPI 1194841452
$871,147.85
in general payments reported to CMS, 2019-2025
80 companies · $92K in 2025
The $92K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $127K · 2020: $113K · 2021: $100K · 2022: $145K · 2023: $179K · 2024: $116K · 2025: $92K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $187K · Consulting Fee: $110K · Travel and Lodging: $39K · Honoraria: $28K · Food and Beverage: $22K · Education: $14.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $187,471.50 |
| Consulting Fee | $109,609.59 |
| Travel and Lodging | $38,680.40 |
| Honoraria | $28,212.50 |
| Food and Beverage | $22,107.44 |
| Education | $14.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $232,162.43 | 2019-2025 | |
| Janssen Biotech, INC. | $138,394.10 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Astellas Pharma US INC | $132,394.34 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Astrazeneca Pharmaceuticals LP | $104,814.66 | 2020-2025 | Lynparza, Truqap, Imfinzi |
| Sn Holdings, LLC | $39,353.30 | 2021-2024 | |
| Pfizer INC. | $36,375.68 | 2019-2025 | |
| Myovant Sciences INC. | $21,059.05 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $18,391.25 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Urogpo LLC | $17,714.49 | 2019-2020 | |
| Clovis Oncology, INC. | $16,493.25 | 2019-2021 | |
| Astrazeneca Uk Limited | $12,490.00 | 2020-2025 | |
| Blue Earth Diagnostics | $12,077.12 | 2019-2025 | Posluma |
| Dendreon Pharmaceuticals LLC | $12,052.82 | 2019-2025 | Provenge |
| Sumitomo Pharma America, INC. | $10,961.57 | 2023-2025 | Orgovyx, Gemtesa |
| Janssen Scientific Affairs, LLC | $10,320.72 | 2019-2025 | Erleada, Pipeline |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $8,291.83 | 2020-2025 | Pylarify |
| Tolmar, INC. | $7,315.52 | 2023-2025 | Rubraca, Eligard, Jatenzo |
| Amgen INC. | $5,615.80 | 2019-2023 | Xgeva |
| Astellas Pharma Global Development | $5,166.54 | 2021-2025 | Xtandi |
| Tolmar Pharmaceuticals, INC. | $3,937.02 | 2019-2022 | |
| Urogen Pharma, INC. | $2,903.90 | 2020-2025 | Jelmyto |
| Ferring Pharmaceuticals INC. | $2,420.05 | 2019-2025 | Adstiladrin |
| Verity Pharmaceuticals INC. | $2,279.13 | 2022-2025 | Tlando, Trelstar |
| Exelixis INC. | $2,238.94 | 2021-2024 | Cabometyx |
| Pharmaand Gmbh | $2,157.41 | 2025 | Rubraca |
| Novartis Pharmaceuticals Corporation | $2,124.86 | 2022-2025 | |
| Daiichi Sankyo INC. | $1,645.00 | 2023 | |
| Myriad Genetic Laboratories, INC. | $1,620.86 | 2020-2025 | Prolaris |
| Abbvie INC. | $1,428.16 | 2019-2025 | |
| Eli Lilly and Company | $862.50 | 2023 | |
| Janssen Pharmaceuticals, INC | $560.59 | 2019-2021 | |
| Janssen Global Services, LLC | $500.00 | 2025 | |
| Endo Pharmaceuticals INC. | $472.61 | 2019-2022 | |
| Allergan, INC. | $406.04 | 2019-2022 | |
| Coloplast Corp | $314.95 | 2021-2024 | Speedicath |
| Axonics, INC. | $247.81 | 2020-2023 | Axonics |
| Urovant Sciences INC | $242.64 | 2021-2022 | |
| Boston Scientific Corporation | $239.14 | 2019-2025 | Ams 700, Moses 550 Dfl |
| Rochester Medical Corporation | $231.58 | 2021-2022 | |
| Telix Pharmaceuticals | $227.38 | 2023-2024 | Illuccix |
| Laborie Medical Technologies Corp. | $224.66 | 2021-2024 | Urgent PC Neuromodulation System |
| Medtronic, INC. | $209.90 | 2022-2024 | Interstim, Ligasure |
| Immunitybio, INC. | $202.59 | 2025 | |
| Cardinal Health INC | $202.05 | 2024 | |
| Angiodynamics, INC. | $166.36 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $148.33 | 2022-2024 | |
| C. R. Bard, INC. & Subsidiaries | $130.91 | 2019-2023 | Bard Urinary Drainage Bag |
| Stryker Corporation | $114.49 | 2023-2025 | Aequalis Ascend Flex, Target, Surpass Evolve |
| Valencia Technologies Corporation | $103.38 | 2025 | Ecoin Device Kit |
| Clarus Therapeutics INC. | $96.77 | 2021 | |
| Accord Healthcare, INC. | $96.45 | 2024-2025 | |
| Antares Pharma, INC. | $96.19 | 2021-2025 | Xyosted |
| Abbott Laboratories | $92.12 | 2019 | |
| Eisai INC. | $87.22 | 2023-2025 | |
| 180 Medical, INC. | $82.95 | 2020-2023 | Gentlecath |
| Procept Biorobotics Corporation | $75.94 | 2022-2025 | Aquabeam Robotic System |
| Vertex Pharmaceuticals Incorporated | $62.51 | 2025 | |
| Olympus America INC. | $51.50 | 2019-2025 | Hd Camera Head |
| E.R. Squibb & Sons, L.L.C. | $42.11 | 2021-2022 | |
| Duchesnay USA Incorporated | $41.68 | 2019 | |
| Photocure INC | $33.18 | 2025 | Cysview |
| Kowa Pharmaceuticals America, INC. | $29.99 | 2023 | Seglentis |
| Hollister Incorporated | $28.08 | 2022 | |
| Baxter Healthcare | $24.52 | 2025 | |
| Halozyme INC | $20.14 | 2023 | |
| Abc Home Medical Supply, INC. | $19.48 | 2022 | |
| Tempus Ai, INC | $19.00 | 2024 | |
| Genmab U.S., INC. | $18.70 | 2025 | |
| Foundation Medicine, INC. | $18.19 | 2020 | |
| Ambu INC. | $17.56 | 2020 | |
| Profound Medical Corp. | $16.76 | 2022 | |
| Bioprotect Medical, INC. | $16.49 | 2025 | Bioprotect Balloon Implant System |
| Zyla Life Sciences, INC. | $14.53 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.36 | 2025 | Azmiro |
| Sagent Pharmaceuticals | $12.20 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.52 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$466.33 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$291,898.13 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.